Association of interleukin-25 levels with development of aspirin induced respiratory diseases

Respiratory Medicine

Volumn 123, Issue , 2017, Pages 71-78

  Lee, Jong Uk ^a   Chang, Hun Soo ^a,b   Lee, Hyeon Ju ^a   Bae, Da Jeong ^a   Son, Ji Hye ^a   Park, Jong Sook ^b   Choi, Jae Sung ^b   Hwang, Hun Gyu ^b   Park, Choon Sik ^a,b  

^a Soonchunhyang University   (South Korea)

^b Soonchunhyang University   (South Korea)

Author keywords

Aspirin; Asthma; IL 25; Innate immune response

Indexed keywords

ACETYLSALICYLIC ACID; IMMUNOGLOBULIN E; INTERLEUKIN 25; INTERLEUKIN 33; LEUKOTRIENE E4; PROSTAGLANDIN D2; THYMIC STROMAL LYMPHOPOIETIN; CYTOKINE; IL25 PROTEIN, HUMAN; IL33 PROTEIN, HUMAN; INTERLEUKIN 17; LEUKOTRIENE C4; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; AGED; ARTICLE; ASPIRIN EXACERBATED RESPIRATORY DISEASE; BRONCHOSPASM; CLINICAL ARTICLE; CONTROLLED STUDY; EOSINOPHIL; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROVOCATION TEST; TH2 CELL; BLOOD; DRUG EFFECTS; IMMUNOLOGY; INNATE IMMUNITY; MIDDLE AGED; PATHOPHYSIOLOGY;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; ASTHMA, ASPIRIN-INDUCED; CYTOKINES; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; IMMUNITY, INNATE; INTERLEUKIN-17; INTERLEUKIN-33; LEUKOTRIENE C4; MALE; MIDDLE AGED; PROSTAGLANDIN D2;

EID: 85007207129     PISSN: 09546111     EISSN: 15323064     Source Type: Journal    
DOI: 10.1016/j.rmed.2016.11.020     Document Type: Article

References (53)

1. [1] Buchheit, K.M., Laidlaw, T.M., Update on the management of aspirin-exacerbated respiratory disease. Allergy, Asthma & Immunol. Res. 8:4 (2016), 298–304.
2. [2] Stevenson, D.D., Sanchez-Borges, M., Szczeklik, A., Classification of allergic and pseudoallergic reactions to drugs that inhibit cyclooxygenase enzymes, Annals of allergy, asthma & immunology: official publication of the American College of Allergy. Asthma, & Immunol. 87:3 (2001), 177–180.
3. [3] Sousa, A.R., Parikh, A., Scadding, G., Corrigan, C.J., Lee, T.H., Leukotriene-receptor expression on nasal mucosal inflammatory cells in aspirin-sensitive rhinosinusitis. N. Engl. J. Med. 347:19 (2002), 1493–1499.
4. [4] Gaber, F., Daham, K., Higashi, A., Higashi, N., Gulich, A., Delin, I., James, A., Skedinger, M., Gyllfors, P., Nord, M., Dahlen, S.E., Kumlin, M., Dahlen, B., Increased levels of cysteinyl-leukotrienes in saliva, induced sputum, urine and blood from patients with aspirin-intolerant asthma. Thorax 63:12 (2008), 1076–1082.
5. [5] Bochenek, G., Nagraba, K., Nizankowska, E., Szczeklik, A., A controlled study of 9alpha,11beta-PGF2 (a prostaglandin D2 metabolite) in plasma and urine of patients with bronchial asthma and healthy controls after aspirin challenge. J. Allergy Clin. Immunol. 111:4 (2003), 743–749.
6. [6] Szczeklik, A., Nizankowska, E., Duplaga, M., Natural history of aspirin-induced asthma. AIANE investigators. European network on aspirin-induced asthma. Eur. Respir. J. 16:3 (2000), 432–436.
7. [7] Min, J.W., Jang, A.S., Park, S.M., Lee, S.H., Lee, J.H., Park, S.W., Park, C.S., Comparison of plasma eotaxin family level in aspirin-induced and aspirin-tolerant asthma patients. Chest 128:5 (2005), 3127–3132.
8. [8] Carpagnano, G.E., Resta, O., Gelardi, M., Spanevello, A., Di Gioia, G., Giliberti, T., Depalo, A., Foschino Barbaro, M.P., Exhaled inflammatory markers in aspirin-induced asthma syndrome. Am. J. Rhinology 21:5 (2007), 542–547.
9. [9] Kupczyk, M., Kurmanowska, Z., Kuprys-Lipinska, I., Bochenska-Marciniak, M., Kuna, P., Mediators of inflammation in nasal lavage from aspirin intolerant patients after aspirin challenge. Respir. Med. 104:10 (2010), 1404–1409.
10. [10] Szczeklik, A., Stevenson, D.D., Aspirin-induced asthma: advances in pathogenesis, diagnosis, and management. J. Allergy Clin. Immunol. 111:5 (2003), 913–921 quiz 922.
11. [11] Barlow, J.L., Peel, S., Fox, J., Panova, V., Hardman, C.S., Camelo, A., Bucks, C., Wu, X., Kane, C.M., Neill, D.R., Flynn, R.J., Sayers, I., Hall, I.P., McKenzie, A.N., IL-33 is more potent than IL-25 in provoking IL-13-producing nuocytes (type 2 innate lymphoid cells) and airway contraction. J. Allergy Clin. Immunol. 132:4 (2013), 933–941.
12. [12] Hung, L.Y., Lewkowich, I.P., Dawson, L.A., Downey, J., Yang, Y., Smith, D.E., Herbert, D.R., IL-33 drives biphasic IL-13 production for noncanonical Type 2 immunity against hookworms. Proc. Natl. Acad. Sci. U. S. A. 110:1 (2013), 282–287.
13. [13] Saenz, S.A., Taylor, B.C., Artis, D., Welcome to the neighborhood: epithelial cell-derived cytokines license innate and adaptive immune responses at mucosal sites. Immunol. Rev. 226 (2008), 172–190.
14. [14] Allakhverdi, Z., Comeau, M.R., Jessup, H.K., Yoon, B.R., Brewer, A., Chartier, S., Paquette, N., Ziegler, S.F., Sarfati, M., Delespesse, G., Thymic stromal lymphopoietin is released by human epithelial cells in response to microbes, trauma, or inflammation and potently activates mast cells. J. Exp. Med. 204:2 (2007), 253–258.
15. [15] Cook, E.B., Stahl, J.L., Schwantes, E.A., Fox, K.E., Mathur, S.K., IL-3 and TNFalpha increase Thymic Stromal Lymphopoietin Receptor (TSLPR) expression on eosinophils and enhance TSLP-stimulated degranulation. Clin. Mol. Allergy CMA, 10(1), 2012, 8.
16. [16] Noti, M., Wojno, E.D., Kim, B.S., Siracusa, M.C., Giacomin, P.R., Nair, M.G., Benitez, A.J., Ruymann, K.R., Muir, A.B., Hill, D.A., et al. Thymic stromal lymphopoietin-elicited basophil responses promote eosinophilic esophagitis. Nat. Med. 19:8 (2013), 1005–1013.
17. [17] Vissinga, C., Martin, T., Jessup, H.K., Comeau, M.R., 269: TSLP driven expansion and activation of type 2 innate lymphoid cells is augmented by IL-25 and IL-33. Cytokine, 63(3), 2013, 307.
18. [18] Allakhverdi, Z., Comeau, M.R., Smith, D.E., Toy, D., Endam, L.M., Desrosiers, M., Liu, Y.J., Howie, K.J., Denburg, J.A., Gauvreau, G.M., Delespesse, G., CD34+ hemopoietic progenitor cells are potent effectors of allergic inflammation. J. Allergy Clin. Immunol. 123:2 (2009), 472–478.
19. [19] Allakhverdi, Z., Smith, D.E., Comeau, M.R., Delespesse, G., Cutting edge: the ST2 ligand IL-33 potently activates and drives maturation of human mast cells. J. Immunol. (Baltim. Md. 1950) 179:4 (2007), 2051–2054.
20. [20] Fallon, P.G., Ballantyne, S.J., Mangan, N.E., Barlow, J.L., Dasvarma, A., Hewett, D.R., McIlgorm, A., Jolin, H.E., McKenzie, A.N., Identification of an interleukin (IL)-25-dependent cell population that provides IL-4, IL-5, and IL-13 at the onset of helminth expulsion. J. Exp. Med. 203:4 (2006), 1105–1116.
21. [21] Xue, L., Salimi, M., Panse, I., Mjosberg, J.M., McKenzie, A.N., Spits, H., Klenerman, P., Ogg, G., Prostaglandin D2 activates group 2 innate lymphoid cells through chemoattractant receptor-homologous molecule expressed on TH2 cells. J. Allergy Clin. Immunol. 133:4 (2014), 1184–1194.
22. [22] Shaw, J.L., Fakhri, S., Citardi, M.J., Porter, P.C., Corry, D.B., Kheradmand, F., Liu, Y.J., Luong, A., IL-33-responsive innate lymphoid cells are an important source of IL-13 in chronic rhinosinusitis with nasal polyps. Am. J. Respir. Crit. Care Med. 188:4 (2013), 432–439.
23. [23] Buchheit, K.M., Cahill, K.N., Katz, H.R., Murphy, K.C., Feng, C., Lee-Sarwar, K., Lai, J., Bhattacharyya, N., Israel, E., Boyce, J.A., Laidlaw, T.M., Thymic stromal lymphopoietin controls prostaglandin D2 generation in patients with aspirin-exacerbated respiratory disease. J. Allergy Clin. Immunol. 137:5 (2016), 1566–1576 e5.
24. [24] Hirai, H., Tanaka, K., Yoshie, O., Ogawa, K., Kenmotsu, K., Takamori, Y., Ichimasa, M., Sugamura, K., Nakamura, M., Takano, S., Nagata, K., Prostaglandin D2 selectively induces chemotaxis in T helper type 2 cells, eosinophils, and basophils via seven-transmembrane receptor CRTH2. J. Exp. Med. 193:2 (2001), 255–261.
25. [25] Nagata, K., Hirai, H., Tanaka, K., Ogawa, K., Aso, T., Sugamura, K., Nakamura, M., Takano, S., CRTH2, an orphan receptor of T-helper-2-cells, is expressed on basophils and eosinophils and responds to mast cell-derived factor(s). FEBS Lett. 459:2 (1999), 195–199.
26. [26] Mjosberg, J.M., Trifari, S., Crellin, N.K., Peters, C.P., van Drunen, C.M., Piet, B., Fokkens, W.J., Cupedo, T., Spits, H., Human IL-25- and IL-33-responsive type 2 innate lymphoid cells are defined by expression of CRTH2 and CD161. Nat. Immunol. 12:11 (2011), 1055–1062.
27. [27] Liu, T., Kanaoka, Y., Barrett, N.A., Feng, C., Garofalo, D., Lai, J., Buchheit, K., Bhattacharya, N., Laidlaw, T.M., Katz, H.R., Boyce, J.A., Aspirin-exacerbated respiratory disease involves a cysteinyl leukotriene-driven IL-33-mediated mast cell activation pathway. J. Immunol. (Baltim. Md. 1950) 195:8 (2015), 3537–3545.
28. [28] Nizankowska-Mogilnicka, E., Bochenek, G., Mastalerz, L., Swierczynska, M., Picado, C., Scadding, G., Kowalski, M.L., Setkowicz, M., Ring, J., Brockow, K., Bachert, C., Wohrl, S., Dahlen, B., Szczeklik, A., EAACI/GA2LEN guideline: aspirin provocation tests for diagnosis of aspirin hypersensitivity. Allergy 62:10 (2007), 1111–1118.
29. [29] Chang, H.S., Park, J.S., Jang, A.S., Park, S.W., Uh, S.T., Kim, Y.H., Park, C.S., Diagnostic value of clinical parameters in the prediction of aspirin-exacerbated respiratory disease in asthma. Allergy, Asthma & Immunol. Res. 3:4 (2011), 256–264.
30. [30] Levy, M.L., Fletcher, M., Price, D.B., Hausen, T., Halbert, R.J., Yawn, B.P., International primary care respiratory group (IPCRG) guidelines: diagnosis of respiratory diseases in primary care. Prim. Care Respir. J. J. General Pract. Airw. Group 15:1 (2006), 20–34.
31. [31] Reh, D.D., Wang, Y., Ramanathan, M. Jr., Lane, A.P., Treatment-recalcitrant chronic rhinosinusitis with polyps is associated with altered epithelial cell expression of interleukin-33. Am. J. Rhinology Allergy 24:2 (2010), 105–109.
32. [32] Guo, Z., Wu, J., Zhao, J., Liu, F., Chen, Y., Bi, L., Liu, S., Dong, L., IL-33 promotes airway remodeling and is a marker of asthma disease severity. J. Asthma Off. J. Assoc. Care Asthma 51:8 (2014), 863–869.
33. [33] Higashi, N., Mita, H., Ono, E., Fukutomi, Y., Yamaguchi, H., Kajiwara, K., Tanimoto, H., Sekiya, K., Akiyama, K., Taniguchi, M., Profile of eicosanoid generation in aspirin-intolerant asthma and anaphylaxis assessed by new biomarkers. The Journal of Allergy and Clinical Immunology 125:5 (2010), 1084–1091 e6.
34. [34] Fort, M.M., Cheung, J., Yen, D., Li, J., Zurawski, S.M., Lo, S., Menon, S., Clifford, T., Hunte, B., Lesley, R., Muchamuel, T., Hurst, S.D., Zurawski, G., Leach, M.W., Gorman, D.M., Rennick, D.M., IL-25 induces IL-4, IL-5, and IL-13 and Th2-associated pathologies in vivo. Immunity 15:6 (2001), 985–995.
35. [35] Ikeda, K., Nakajima, H., Suzuki, K., Kagami, S., Hirose, K., Suto, A., Saito, Y., Iwamoto, I., Mast cells produce interleukin-25 upon Fc epsilon RI-mediated activation. Blood 101:9 (2003), 3594–3596.
36. [36] Moon, T.C., Befus, A.D., Kulka, M., Mast cell mediators: their differential release and the secretory pathways involved. Front. Immunol., 5, 2014, 569.
37. [37] Kong, S.-K., Soo Kim, B., Gi Uhm, T., Soo Chang, H., Sook Park, J., Woo Park, S., Park, C.-S., Chung, I.Y., Aspirin induces IL-4 production: augmented IL-4 production in aspirin-exacerbated respiratory disease. Exp. Mol. Med., 47(12), 2015, e00.
38. [38] Varga, E.M., Jacobson, M.R., Masuyama, K., Rak, S., Till, S.J., Darby, Y., Hamid, Q., Lund, V., Scadding, G.K., Durham, S.R., Inflammatory cell populations and cytokine mRNA expression in the nasal mucosa in aspirin-sensitive rhinitis. Eur. Respir. J. 14:3 (1999), 610–615.
39. [39] Steinke, J.W., Payne, S.C., Borish, L., Interleukin-4 in the generation of the AERD phenotype: implications for molecular mechanisms driving therapeutic benefit of aspirin desensitization. J. Allergy, 2012, 2012, 182090.
40. [40] Kopp, E., Ghosh, S., Inhibition of NF-kappa B by sodium salicylate and aspirin. Sci. (New York, N.Y.) 265:5174 (1994), 956–959.
41. [41] Schwenger, P., Skolnik, E.Y., Vilcek, J., Inhibition of tumor necrosis factor-induced p42/p44 mitogen-activated protein kinase activation by sodium salicylate. J. Biol. Chem. 271:14 (1996), 8089–8094.
42. [42] Perez, G.M., Melo, M., Keegan, A.D., Zamorano, J., Aspirin and salicylates inhibit the IL-4- and IL-13-induced activation of STAT6. J. Immunol. (Baltim. Md. 1950) 168:3 (2002), 1428–1434.
43. [43] Steinke, J.W., Culp, J.A., Kropf, E., Borish, L., Modulation by aspirin of nuclear phospho-signal transducer and activator of transcription 6 expression: possible role in therapeutic benefit associated with aspirin desensitization. J. Allergy Clin. Immunol. 124:4 (2009), 724–730 e4.
44. [44] Kim, B.S., Park, S.M., Uhm, T.G., Kang, J.H., Park, J.S., Jang, A.S., Uh, S.T., Kim, M.K., Choi, I.S., Cho, S.H., Hong, C.S., Lee, Y.W., Lee, J.Y., Choi, B.W., Park, H.S., Park, B.L., Shin, H.D., Chung, I.Y., Park, C.S., Effect of single nucleotide polymorphisms within the interleukin-4 promoter on aspirin intolerance in asthmatics and interleukin-4 promoter activity. Pharmacogenetics Genomics 20:12 (2010), 748–758.
45. [45] Schwenger, P., Alpert, D., Skolnik, E.Y., Vilcek, J., Activation of p38 mitogen-activated protein kinase by sodium salicylate leads to inhibition of tumor necrosis factor-induced IkappaB alpha phosphorylation and degradation. Mol. Cell. Biol. 18:1 (1998), 78–84.
46. [46] Kong, S.-K., Soo Kim, B., Gi Uhm, T., Soo Chang, H., Sook Park, J., Woo Park, S., Park, C.-S., Chung, I.Y., Aspirin induces IL-4 production: augmented IL-4 production in aspirin-exacerbated respiratory disease. Exp. Mol. Med., 48(1), 2016, e202.
47. [47] Gerli, R., Paolucci, C., Gresele, P., Bistoni, O., Fiorucci, S., Muscat, C., Belia, S., Bertotto, A., Costantini, V., Salicylates inhibit adhesion and transmigration of T lymphocytes by preventing integrin activation induced by contact with endothelial cells. Blood 92:7 (1998), 2389–2398.
48. [48] Flescher, E., Fossum, D., Gray, P.J., Fernandes, G., Harper, M.J., Talal, N., Aspirin-like drugs prime human T cells. Modulation of intracellular calcium concentrations. J. Immunol. (Baltim. Md. 1950) 146:8 (1991), 2553–2559.
49. [49] Schwenger, P., Alpert, D., Skolnik, E.Y., Vilcek, J., Cell-type-specific activation of c-Jun N-terminal kinase by salicylates. J. Cell. Physiology 179:1 (1999), 109–114.
50. [50] Mifflin, R.C., Saada, J.I., Di Mari, J.F., Valentich, J.D., Adegboyega, P.A., Powell, D.W., Aspirin-mediated COX-2 transcript stabilization via sustained p38 activation in human intestinal myofibroblasts. Mol. Pharmacol. 65:2 (2004), 470–478.
51. [51] Kim, J.H., Park, B.L., Cheong, H.S., Bae, J.S., Park, J.S., Jang, A.S., Uh, S.T., Choi, J.S., Kim, Y.H., Kim, M.K., Choi, I.S., Cho, S.H., Choi, B.W., Park, C.S., Shin, H.D., Genome-wide and follow-up studies identify CEP68 gene variants associated with risk of aspirin-intolerant asthma. PloS One, 5(11), 2010, e13818.
52. [52] Park, B.L., Kim, T.H., Kim, J.H., Bae, J.S., Pasaje, C.F., Cheong, H.S., Kim, L.H., Park, J.S., Lee, H.S., Kim, M.S., Choi, I.S., Choi, B.W., Kim, M.K., Shin, S., Shin, H.D., Park, C.S., Genome-wide association study of aspirin-exacerbated respiratory disease in a Korean population. Hum. Genet. 132:3 (2013), 313–321.
53. [53] Shin, S.W., Park, B.L., Chang, H., Park, J.S., Bae, D.J., Song, H.J., Choi, I.S., Kim, M.K., Park, H.S., Kim, L.H., Namgoong, S., Kim, J.O., Shin, H.D., Park, C.S., Exonic variants associated with development of aspirin exacerbated respiratory diseases. PloS One, 9(11), 2014, e111887.